



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/586,338

08/15/2006

Shinji Yokoyama

2006\_1127A

2790

513 7590 06/30/2009

WENDEROTH, LIND & PONACK, L.L.P.

1030 15th Street, N.W.,

Suite 400 East

Washington, DC 20005-1503

EXAMINER

ZAREK, PAUL E

ART UNIT

PAPER NUMBER

1617

MAIL DATE

DELIVERY MODE

06/30/2009

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/586,338	<b>Applicant(s)</b> YOKOYAMA ET AL.	
	<b>Examiner</b> Paul Zarek	<b>Art Unit</b> 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 18 May 2009.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 6 and 7 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) 6 and 7 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All    b) ☐ Some \*    c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

Art Unit: 1617

## **DETAILED ACTION**

### ***Status of the Claims***

1. Claims 6 and 7 have been added and Claims 1-5 have been cancelled by the Applicant in correspondence filed on 05/18/2009. Claims 6 and 7 are currently pending. This is the second Office Action on the merits of the claim(s).

## **RESPONSE TO ARGUMENTS**

2. Claims 2-4 were rejected under 35 U.S.C. 112, first paragraph, for not being enabled for the prophylaxis of cholesterolemia or arteriosclerosis. This rejection is moot in light of the cancellation of Claims 2-4.

3. Claim 4 was rejected under 35 U.S.C. 112, second paragraph, as being indefinite. This rejection is moot in light of the cancellation of Claim 4.

4. Claims 1-5 were rejected under 35 U.S.C. 102(b) as being anticipated by Stocker (International Application WO 02/04031, provided in IDS). This rejection is moot in light of the cancellation of Claims 1-5.

5. Claims 1-3 and 5 were rejected under 35 U.S.C. 102(b) as being anticipated by McLean, et al. (Lipids, 1994, provided in IDS). This rejection is moot in light of the cancellation of Claims 1-3 and 5.

6. Newly added Claims 6 and 7 are examined on their merits and the following **FINAL** rejection is made.

***Claim Rejections - 35 USC § 112 (2<sup>nd</sup> paragraph)***

7. The text of Title 35, U.S.C. § 112, second paragraph, can be found in a prior Office action.

8. Claims 6 and 7 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The rejected claims recite the limitation that the compounds will be administered to a patient in need of increased ABCA1 expression. Neither the claims nor the specification define such a patient population. Thus, the metes and bounds of the claims are unclear and indefinite. For prior art purposes, “a patient in need thereof” shall be interpreted to include any patient.

***Claim Rejections - 35 USC § 102***

9. The text of Title 35, U.S.C. § 102(b) can be found in a prior Office action.

10. Claim 6 is rejected under 35 U.S.C. 102(b) as being anticipated by Stocker (above).

Claim 6 of the instant application is drawn to a method for increasing expression of ABCA1 comprising administration of probucol spiroquinone, probucol diphenquinone, or probucol bisphenol to a patient in need thereof. Examiner notes that the increased expression of ABCA1 is the intended result of the method, and not considered a patentably distinguishing feature of the invention. (see *Hoffer v. Microsoft Corp.*, 405 F.3d 1326, 1329, 74 USPQ2d 1481, 1483 (Fed. Cir. 2005) (MPEP § 2111.04))

Art Unit: 1617

13. Stocker teaches a method of administering chow containing probucol bisphenol to mice (pg 8, Figures 5-7). Stocker does not disclose the effect of probucol bisphenol on ABCA1 expression in these mice. Applicants state that the “present invention is based on the novel discovery that . . . probucol bisphenol (BH) [is an] effective stabilizer for ABCA1.” (Reply filed 05/18/2009, pg 6, lines 1-2). “[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art’s functioning, does not render the old composition patentably new to the discoverer.’ *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977)” (MPEP § 2112(II)). Oral administration of probucol bisphenol would inherently increase ABCA1 expression, regardless of whether such a property was appreciated by Stocker. Therefore, Stocker anticipates all the limitations of the rejected claim.

### ***Claim Rejections - 35 USC § 103***

14. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

15. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any

Art Unit: 1617

evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

16. Claim 7 is rejected under 35 U.S.C. 103(a) as being unpatentable over Stocker (above).

17. Claim 7 limits the method of Claim 6 to further include an additional drug, such as an antithrombic drug.

18. Stocker teaches that probucol bisphenol promotes re-endothelialization of damaged vessel walls, *in vivo*. Antithrombic (aka thrombolytic) drugs would inhibit thrombosis of the new vasculature. Both probucol bisphenol and antithrombic drugs would be useful for the treatment of damaged vessel walls. "It is *prima facie* obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." *In re Kerkhoven*, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) (MPEP § 2144.06(I)). Therefore, it would have been *prima facie* obvious to one of ordinary skill in the art to combine probucol bisphenol and an antithrombic drug.

### ***Conclusion***

19. Claims 6 and 7 are rejected.

Art Unit: 1617

20. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

21. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Paul Zarek whose telephone number is (571) 270-5754. The examiner can normally be reached on Monday-Thursday, 7:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1617

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

PEZ

/San-ming Hui/  
Primary Examiner, Art Unit 1617